Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) the creator of Smart CapnographyTM - announced today that it was selected as the recipient of the North American “2010 Customer Value Enhancement Award” by Frost & Sullivan, a leading global consulting company. The Award recognizes Oridion’s focus on enhancing the value it delivers to its customers, its ability to understand and recognize the ventilation monitoring market’s dynamic needs, and its unparalleled technology leadership, all of which have enabled Oridion to effect major improvements in ventilation monitoring.
Jerusalem/Needham (PRWEB) February 18, 2010 -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) the creator of Smart CapnographyTM - announced today that it was selected as the recipient of the North American “2010 Customer Value Enhancement Award” by Frost & Sullivan, a leading global consulting company. The Award recognizes Oridion’s focus on enhancing the value it delivers to its customers, its ability to understand and recognize the ventilation monitoring market’s dynamic needs, and its unparalleled technology leadership, all of which have enabled Oridion to effect major improvements in ventilation monitoring.
The award by Frost & Sullivan recognizes Oridion’s approach to enhance customer value and its efforts in advancing ventilation monitoring technology to improve patient safety and care. Oridion demonstrates that capnography monitoring is exceptionally useful to assure patient safety in intensive care units, emergency response, procedural sedation and pain management. It has expanded the growing and evolving capnography market and succeeded in accelerating capnography’s penetration into existing and new clinical environments in which it fulfills important, previously unmet clinical needs.
“Oridion has enhanced perceived value within the capnography market through three key elements – (1) by promoting the improved safety and necessity of capnography monitoring, (2) through well-executed targeting of key environments in the healthcare system, and (3) through the continuing innovation and quality of its products and services”, says Frost & Sullivan Industry Analyst Zachary Bujnoch. “These interweaving factors have allowed Oridion to not only enhance customer value within the capnography market, but also further penetrate the market as a whole. Oridion has been the prime mover in establishing capnography and, in particular, Microstream® as the leader in ventilation monitoring.”
Frost & Sullivan also recognizes the potential contribution of Oridion’s new key Smart Capnography offering, the Integrated Pulmonary Index™ (IPI). IPI integrates four parameters (end-tidal CO2, respiration rate, pulse rate and oxygen saturation SpO2) into a single index value. This value holds the promise of a quicker and more complete evaluation of a patient’s respiratory status at a single glance. It also has the potential to increase the perceived value of capnography and ventilation monitoring in the eyes of customers and end users. This is especially the case in environments in which the caregivers are not specialists in anesthesia and ventilation, such as general floor nurses or procedural sedation personnel. And, by trending the new index, hospital personnel will be provided with even more actionable decision-support data.
“Our mission at Oridion is to improve medicine and save lives. We do this by always being focused on bringing the best solutions to the market and delivering major improvements in value to our partners, customers and end-users. A measure of our success is that, despite the current economic constraints, more and more health care systems have embraced Oridion Microstream capnography as their life saving solution wherever patients at risk of ventilatory depression are treated. We are honored that our approach and results have been recognized by Frost & Sullivan with the selection of Oridion for this fine Award,” commented Gerry Feldman, President of Oridion.
For the original press release issued by Frost & Sullivan go to: http://www.frost.com/prod/servlet/press-en-releases-index.pag
For further Oridion information please contact:
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
phone: +972 2 589 9159
address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient’s breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients’ ventilation may be compromised and at risk.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1,000 companies, emerging businesses and the investment community from 40 offices on six continents. For more information, please visit http://www.awards.frost.com.
Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.
The Company does not assure any obligation to update the forward looking information contained in this press release.
Read the full story at http://www.prweb.com/releases/2010/02/prweb3615844.htm.
Copyright©2010 Vocus, Inc.
All rights reserved